Clinical trials: Vinorelbine
Breast Cancer
Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004237
- Testing
- cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride
- Where
- United Kingdom
- Sponsor
- Royal Marsden NHS Foundation Trust
Myeloma
PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma
High-dose chemotherapy with autologous stem cell support is the current standard procedure in the first-line treatment in younger patients with myeloma fit for intensive treatment.
- Trial name
- PAV (NCT01220375)
- Testing
- Vinorelbine, G-CSF, & Plerixafor, Vinorelbine and Plerixafor, G-CSF and Plerixafor
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Elderly Patients, Metastatic Lung Cancer
Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
Lung cancer is the cancer with the highest morbidity and mortality among men in the world. The proportion of elderly lung cancer patients in the global lung cancer population is steadily increasing, at the same time, it is also…
- Trial name
- NCT06032052
- Testing
- Single drug chemotherapy plus immunotherapy
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Hubei Cancer Hospital
Breast Neoplasms, BRCA 1 Gene Mutation
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or…
- Conditions
- Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
- Trial name
- EMBRACA (NCT01945775)
- Testing
- talazoparib, Physician's-Choice
- Where
- 362 sites in United States, Australia and 14 more
- Volunteers
- 431 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)
To investigate the maximum tolerated dose of BIBF 1120, safety and pharmacokinetics in escalating doses administered with Vinorelbine i.v. in elderly patients with advanced Non-Small Lung Cancer (Stage IV).
- Trial name
- VENUS-1 (NCT01684111)
- Testing
- BIBF 1120, Vinorelbine
- Where
- 4 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Aktion Bronchialkarzinom e.V.
Hodgkin Disease
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
Patients with 3 or more adverse prognostic factors have a higher relapse rate. Significant anti-tumor activity in Hodgkin's lymphoma has been reported with two new drugs:gemcitabine and vinorelbine.
- Trial name
- NCT00225173
- Testing
- Doxorubicin, Vinblastine, Cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stanford University
Recurrent or Metastatic Breast Cancer
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
This study is a multicenter, randomized, open-label, parallel-control Phase III clinical trial enrolling patients with unresectable HER2-negative, EGFR-positive recurrent/metastatic breast cancer who have previously failed first…
- Trial name
- NCT07406542
- Testing
- SYS6010, Investigator's Choice of Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine)
- Volunteers
- 400 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Breast Cancer
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.
- Trial name
- NCT01254136
- Testing
- INCB007839 300mg BID, Trastuzumab, Vinorelbine
- Where
- 14 sites in United States
- Volunteers
- 20 people
- Sponsor
- Incyte Corporation
Metastatic Breast Cancer
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Trastuzumab or Herceptin is an antibody directed against Her-2. Her-2 is a growth factor receptor which is present on the tumors of 25% of patients with breast cancer.
- Trial name
- NCT00169104
- Testing
- G-CSF, trastuzumab, vinorelbine
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Squamous Cell Esophageal Carcinoma
Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer
The primary objective is to compare neo-adjuvant chemoradiotherapy followed by surgery versus surgery, in terms of the overall survival time (OS) in patients with Stage IIB or III squamous cell esophageal carcinoma.
- Trial name
- NCT01216527
- Testing
- Neo-adjuvant Chemoradiotherapy followed by Surgery, surgery
- Where
- 2 sites in China
- Volunteers
- 430 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine plus paclitaxel in treating patients with…
- Trial name
- NCT00003622
- Testing
- paclitaxel, vinorelbine tartrate
- Where
- United States
- Sponsor
- James Ahlgren
Triple Negative Breast Cancer, Metastatic Breast Cancer
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
The goal of this clinical trial is to evaluate the efficacy of investigator's choice of chemotherapy, either alone or in combination with everolimus, in treating patients with locally recurrent inoperable or metastatic…
- Conditions
- Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation
- Trial name
- BCTOP-T-M03 (NCT05954442)
- Testing
- Everolimus, Investigator's Choice of Chemotherapy
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Fudan University
Lung Cancer
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
The purpose of this study is to determine whether a combination of the drugs docetaxel (Taxotere ® ), plus vinorelbine (Navelbine ® ), will result in fewer side effects than cisplatin chemotherapy, thereby improving delivery of…
- Trial name
- NCT00675597
- Testing
- Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Triple-negative Breast Cancer
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of Inosine with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.
- Trial name
- NCT06355024
- Testing
- Inosine, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer
The combination of vinorelbine with weekly trastuzumab has produced high response rate in HER2 overexpressing metastatic breast cancer (MBC).
- Trial name
- NCT00401427
- Testing
- trastuzumab, vinorelbine
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute, Naples
Breast Neoplasms, Neoplasm Metastasis
Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
This study will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and vinorelbine therapy in patients with HER-2 overexpressing metastatic breast cancer.
- Trial name
- NCT00426530
- Testing
- everolimus (RAD001)
- Where
- 6 sites in Belgium, France and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Low-Grade Glioma
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
The purpose of this study is to determine whether oral vinorelbine is effective in the treatment of children with progressive or recurrent unresectable low grade glioma.
- Trial name
- OVIMA-1210 (NCT02197637)
- Testing
- ORAL VINORELBINE
- Where
- 16 sites in France
- Volunteers
- 39 people
- Sponsor
- Centre Oscar Lambret
Non-Small Cell Lung Cancer
Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
60% of all malignant diseases occur in patients who are 65 years or older. For these patients, aggressive treatments are often not suitable due to reduced life-expectancy, reduced general condition, comorbidities, and reduced…
- Trial name
- TIE (NCT00678964)
- Testing
- Erlotinib, Vinorelbine and Carboplatin
- Where
- 40 sites in Germany
- Volunteers
- 260 people
- Sponsor
- LungenClinic Grosshansdorf
Carcinoma, Non-Small-Cell Lung
Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
Primary objective of the study's Safety run-in: To determine the maximum tolerated dose (MTD) of cilengitide in combination with cetuximab, and platinum-based chemotherapy (cisplatin/vinorelbine or cisplatin/gemcitabine).
- Trial name
- CERTO (NCT00842712)
- Testing
- Cilengitide, Cetuximab, Cisplatin
- Where
- 44 sites in Belgium, Czechia and 6 more
- Volunteers
- 232 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lung Cancer
Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery
RATIONALE: Determination of genetic changes in patients with non-small cell lung cancer may help predict the outcome of treatment.
- Trial name
- NCT00057798
- Testing
- gemcitabine hydrochloride, vinorelbine ditartrate, cytogenetic analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute